Terms: = Lung cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
137 results:
1. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.
Gupta N; Hanley MJ; Griffin RJ; Zhang P; Venkatakrishnan K; Sinha V
Clin Pharmacokinet; 2023 Aug; 62(8):1063-1079. PubMed ID: 37493887
[TBL] [Abstract] [Full Text] [Related]
2. Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell lung cancer.
Fan R; Zhao J; Wang B; Li X; Guan Y; Ren P; Sun R; Zhang L; Guo Y
Genet Test Mol Biomarkers; 2022 Dec; 26(12):582-588. PubMed ID: 36577124
[No Abstract] [Full Text] [Related]
3. The roles of Cyp1a2 and cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Qin X; Xie C; Hakenjos JM; MacKenzie KR; Boyd SR; Barzi M; Bissig KD; Young DW; Li F
Eur J Pharm Sci; 2023 Feb; 181():106358. PubMed ID: 36513193
[TBL] [Abstract] [Full Text] [Related]
4. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
5. Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of cyp2d6 by dacomitinib.
Qiu X; Ren B; Lian Y; Fang L; Dong Z
J Oncol Pharm Pract; 2023 Jun; 29(4):1002-1005. PubMed ID: 36380705
[TBL] [Abstract] [Full Text] [Related]
6. Association of genetic polymorphisms of CYP3A4 and cyp2d6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract] [Full Text] [Related]
7. Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559.
Verma SK; Biswas A; Kumar M; Mishra A; Choudhury AD; Agrawal S; Sanap SN; Bisen AC; Sharma AK; Panda G; Bhatta RS
Xenobiotica; 2022 May; 52(5):476-487. PubMed ID: 35819259
[TBL] [Abstract] [Full Text] [Related]
8. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
Qiao F; Chen Q; Lu W; Fang N
Medicine (Baltimore); 2022 Jul; 101(27):e29629. PubMed ID: 35801736
[TBL] [Abstract] [Full Text] [Related]
9. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.
Heersche N; Veerman GDM; de With M; Bins S; Assaraf YG; Dingemans AC; van Schaik RHN; Mathijssen RHJ; Jansman FGA
Drug Resist Updat; 2022 May; 62():100832. PubMed ID: 35427871
[TBL] [Abstract] [Full Text] [Related]
10. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract] [Full Text] [Related]
11. Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Int Immunopharmacol; 2021 Nov; 100():108087. PubMed ID: 34464888
[TBL] [Abstract] [Full Text] [Related]
12. Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.
Luo R; Ge C; Xiao X; Song J; Miao S; Tang Y; Lai J; Nian W; Song F; Ran L
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013324
[TBL] [Abstract] [Full Text] [Related]
13. Effects of dacomitinib on the pharmacokinetics of poziotinib
Ji W; Shen J; Wang B; Chen F; Meng D; Wang S; Dai D; Zhou Y; Wang C; Zhou Q
Pharm Biol; 2021 Dec; 59(1):457-464. PubMed ID: 33899675
[TBL] [Abstract] [Full Text] [Related]
14. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract] [Full Text] [Related]
15. Profile of the inhibitory effects of gefitinib on cyp2d6 variants in vitro.
Semba Y; Akiyoshi T; Hibino H; Imaoka A; Ohtani H
Int J Clin Pharmacol Ther; 2020 Oct; 58(10):539-542. PubMed ID: 32691726
[TBL] [Abstract] [Full Text] [Related]
16. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
[TBL] [Abstract] [Full Text] [Related]
17. Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer.
Perlík F
Cent Eur J Public Health; 2020 Mar; 28(1):53-58. PubMed ID: 32228818
[TBL] [Abstract] [Full Text] [Related]
18. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity.
Zhao C; Hao H; Zhao H; Ren W; Jiao Y; An G; Sun H; Han S; Li P
J Ethnopharmacol; 2020 Jun; 255():112770. PubMed ID: 32205262
[TBL] [Abstract] [Full Text] [Related]
19. Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility.
Li M; Li A; He R; Dang W; Liu X; Yang T; Shi P; Bu X; Gao D; Zhang N; Du S; Jin T; Chen M
Cancer Med; 2019 Aug; 8(10):4892-4905. PubMed ID: 31264381
[TBL] [Abstract] [Full Text] [Related]
20. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract] [Full Text] [Related]
[Next]
